Almirall secures EIB loan to develop treatments for skin diseases

Emendo raises $61m to accelerate novel gene editing platform
Credit: arka38

Spanish pharmaceutical company, Almirall, has secured a €120 million loan from the European Investment Bank (EIB) to fund research into new skin disease treatments.

The funding comes under the Investment Plan for Europe and will bankroll new research into new therapeutic indications to benefit patients with severe skin diseases for which there is currently no effective pharmaceutical treatment.

Almirall said that with the support of the EIB it will be able to execute its research, development and innovation (RDI) focused on developing transformative therapies to improve the quality of life of patients with inflammatory dermatological diseases, selected cutaneous cancers and rare congenital disorders with no effective treatment available.

The research will specifically focus on new therapies for atopic dermatitis, psoriasis, actinic keratosis, and effective treatment for a congenital disease such as epidermolysis bullosa.